111 related articles for article (PubMed ID: 11724358)
1. Effects of topoisomerase II inhibitors on gastric cancer cells characterized by different genetic lesions.
Scovassi AL; Pellegata NS; Di Stefano L; Padovan L; Negri C; Prosperi E; Riva F; Ciomei M; Ranzani GN
Anticancer Res; 2001; 21(4A):2803-8. PubMed ID: 11724358
[TBL] [Abstract][Full Text] [Related]
2. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
3. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
4. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells.
Jiang XH; Wong BC; Lin MC; Zhu GH; Kung HF; Jiang SH; Yang D; Lam SK
Oncogene; 2001 Nov; 20(55):8009-18. PubMed ID: 11753684
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis and cell cycle arrest in glioma cells by GL331 (a topoisomerase II inhibitor).
Chen Y; Su YH; Wang CH; Wu JM; Chen JC; Tseng SH
Anticancer Res; 2005; 25(6B):4203-8. PubMed ID: 16309217
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase II inhibitor, etoposide, induces p21WAF1/CIP1 through down-regulation of c-Myc in K562 cells.
Horiguchi-Yamada J; Fukumi S; Saito S; Nakayama R; Iwase S; Yamada H
Anticancer Res; 2002; 22(6C):3827-32. PubMed ID: 12553001
[TBL] [Abstract][Full Text] [Related]
7. Cellular response to etoposide treatment.
Montecucco A; Biamonti G
Cancer Lett; 2007 Jul; 252(1):9-18. PubMed ID: 17166655
[TBL] [Abstract][Full Text] [Related]
8. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
9. The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines.
Schmidt F; Knobbe CB; Frank B; Wolburg H; Weller M
Oncol Rep; 2008 Apr; 19(4):1061-6. PubMed ID: 18357397
[TBL] [Abstract][Full Text] [Related]
10. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc.
Bidwell GL; Raucher D
Biochem Pharmacol; 2006 Jan; 71(3):248-56. PubMed ID: 16316634
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis of androgen-independent mammary and prostate cell lines induced by topoisomerase inhibitors: common pathway of gene regulation.
Furuya Y; Ohta S; Ito H
Anticancer Res; 1997; 17(3C):2089-93. PubMed ID: 9216669
[TBL] [Abstract][Full Text] [Related]
12. G2 arrest in response to topoisomerase II inhibitors: the role of p53.
Clifford B; Beljin M; Stark GR; Taylor WR
Cancer Res; 2003 Jul; 63(14):4074-81. PubMed ID: 12874009
[TBL] [Abstract][Full Text] [Related]
13. Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells.
Chiu CC; Li CH; Ung MW; Fuh TS; Chen WL; Fang K
Cancer Lett; 2005 Jun; 223(2):249-58. PubMed ID: 15896459
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
Richie JP
J Urol; 2005 Sep; 174(3):931-2. PubMed ID: 16093994
[No Abstract] [Full Text] [Related]
15. Cycloheximide protects HepG2 cells from serum withdrawal-induced apoptosis by decreasing p53 and phosphorylated p53 levels.
Bai J; Cederbaum AI
J Pharmacol Exp Ther; 2006 Dec; 319(3):1435-43. PubMed ID: 16971506
[TBL] [Abstract][Full Text] [Related]
16. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
17. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
Ramirez PT; Gershenson DM; Tortolero-Luna G; Ramondetta LM; Fightmaster D; Wharton JT; Wolf JK
Gynecol Oncol; 2001 Dec; 83(3):543-8. PubMed ID: 11733969
[TBL] [Abstract][Full Text] [Related]
18. The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs.
Potter AJ; Rabinovitch PS
Mutat Res; 2005 May; 572(1-2):27-44. PubMed ID: 15790488
[TBL] [Abstract][Full Text] [Related]
19. Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines.
Brown GA; McPherson JP; Gu L; Hedley DW; Toso R; Deuchars KL; Freedman MH; Goldenberg GJ
Cancer Res; 1995 Jan; 55(1):78-82. PubMed ID: 7805045
[TBL] [Abstract][Full Text] [Related]
20. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
Baptiste N; Friedlander P; Chen X; Prives C
Oncogene; 2002 Jan; 21(1):9-21. PubMed ID: 11791172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
